Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

To be able to take part in this study, you would need to have been diagnosed with multiple myeloma that is causing symptoms and can be measured. Your cancer must have either come back or not responded to previous treatments, and you must need new therapy. You should have already received at least two lines of treatment for your multiple myeloma. For example, if you had initial treatment followed by a stem cell transplant and then further treatment, this would count as one line of therapy.

It's important that you've also previously been treated with both lenalidomide and a proteasome inhibitor (another type of drug) and that these treatments haven't worked well enough. This could mean your disease got worse during or soon after taking them, or you didn't have a good enough response after several cycles, or you couldn't tolerate the medicines. You also need to have received enough of an "alkylator" type of drug, such as during a stem cell transplant or a few cycles of treatment.

Beyond your cancer history, you would need to be generally well enough to participate, with a life expectancy of at least 3 months and a good general fitness level (as assessed by your doctor). Your blood tests, specifically your neutrophil and platelet counts, would also need to be within a certain range. The study is open to both men and women, aged 18 and over.

If you decide to take part in this study, you will be randomly assigned to one of two groups, like flipping a coin. One group will receive a combination of pomalidomide, dexamethasone, and cyclophosphamide. The other group will receive pomalidomide and dexamethasone. You or your doctor won't be able to choose which group you are in. You will continue to receive the assigned treatment until your disease starts to get worse or if you experience side effects that are too difficult to manage.

Taking part will involve regular visits to the hospital for assessments, blood tests, and to receive your medication. The specific schedule and duration of these visits will be explained in detail by the study team. You will be closely monitored throughout the study to track your progress and any side effects. The total duration of your participation will depend on how your disease responds to treatment and whether you experience any unacceptable side effects.